Semaglutide dosing schedule
Sample dosing schedule
Important: in clinical studies the dose was increased gradually from the lowest starting point; jumping to a high dose too soon is associated with pronounced and long-lasting adverse effects (mostly gastrointestinal). Many do not need to reach the maximum dose. This information is provided for reference only; the product is intended for laboratory research and not for use in humans or animals.
| Weeks | Weekly dose | Stage |
|---|---|---|
| Week 1–4 | 0.25 mg | Initial onboarding dose |
| Week 5–8 | 0.5 mg | Dose escalation (if needed) |
| Week 9–12 | 1 mg | Dose escalation (if needed) |
| Week 13–16 | 1.7 mg | Dose escalation (if needed) |
| Week 17+ | 2.4 mg | Maximum indicated dose |
About the compound
Semaglutide is a GLP-1 receptor agonist. Research examines its effect on glycemic control via glucose-dependent insulin secretion, and on appetite and body weight.
The data is provided for reference only.